These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 19878335)

  • 41. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs.
    Santagostino E; Morfini M; Auerswald GK; Benson GM; Salek SZ; Lambert T; Salaj P; Jimenez-Yuste V; Ljung RC
    Haemophilia; 2009 Sep; 15(5):983-9. PubMed ID: 19712172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors.
    Rangarajan S; Yee TT; Wilde J
    Haemophilia; 2011 Jan; 17(1):28-34. PubMed ID: 20642787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors.
    Livnat T; Budnik I; Levy-Mendelovich S; Avishai E; Misgav M; Barg AA; Lubetsky A; Brutman-Barazani T; Kenet G
    Blood Cells Mol Dis; 2017 Jul; 66():1-5. PubMed ID: 28689155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
    Teitel J; Berntorp E; Dolan G; Fischer K; Gringeri A; Kessler C; Lambert T; Leissinger C; Nemes L; Shima M
    Haemophilia; 2011 May; 17(3):516-21. PubMed ID: 21371181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P; Klementz G
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
    Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
    Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors.
    Medeiros D; Laufenberg JA; Miller KL; Buchanan GR
    Haemophilia; 2007 Jan; 13(1):85-9. PubMed ID: 17212730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
    Young G; Auerswald G; Jimenez-Yuste V; Lambert T; Morfini M; Santagostino E; Blanchette V
    Thromb Res; 2012 Dec; 130(6):864-70. PubMed ID: 22964026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
    Leissinger CA; Singleton T; Kruse-Jarres R
    Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
    N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
    Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
    Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports.
    Streif W; Escuriola Ettingshausen C; Linde R; Kropshofer G; Zimmerhackl LB; Kreuz W
    Hamostaseologie; 2009 May; 29(2):151-4. PubMed ID: 19404522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
    Dargaud Y; Lienhart A; Meunier S; Hequet O; Chavanne H; Chamouard V; Marin S; Negrier C
    Haemophilia; 2005 Sep; 11(5):552-8. PubMed ID: 16128902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.